Recent Market Performance and Price Movements
On 26 December 2025, Entero Healthcare Solutions recorded a decline of 1.23% in its share price, underperforming the Sensex which moved down by 0.50% on the same day. The stock also fell short of its sector’s performance by 0.46%, indicating relative weakness within its industry group. Trading below all major moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — the stock’s technical indicators suggest sustained downward momentum.
Over the past week, the stock’s price shifted by -0.64%, contrasting with a marginal 0.06% gain in the Sensex. The one-month period saw a sharper decline of 9.10%, while the broader market index moved down by 0.74%. The three-month timeframe highlights a more pronounced divergence, with Entero Healthcare Solutions falling by 11.98% as the Sensex advanced by 5.66%.
Yearly figures further illustrate the stock’s relative underperformance. Over the last 12 months, the company’s shares have declined by 32.58%, whereas the Sensex has appreciated by 8.29%. Year-to-date data echoes this trend, with the stock down 32.40% compared to the Sensex’s 8.75% rise. Notably, the stock has not recorded any gains over the past three, five, and ten years, remaining flat while the Sensex has posted substantial returns of 40.30%, 80.91%, and 228.88% respectively.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Long-Term Financial Trends and Growth Metrics
Despite the subdued share price performance, Entero Healthcare Solutions has demonstrated notable growth in its core financial metrics. The company’s net sales have expanded at an annual rate of 30.10%, signalling a robust top-line trajectory over recent periods. Operating profit has shown an even more substantial increase, rising by 127.38% annually, reflecting operational efficiencies or margin improvements.
Quarterly results reveal a consistent positive trend, with the company reporting gains for seven consecutive quarters. The latest quarter recorded net sales at Rs.1,570.95 crore, the highest to date. Correspondingly, the profit before depreciation, interest, and taxes (PBDIT) reached Rs.62.06 crore, also a record high. The operating profit margin relative to net sales stood at 3.95%, marking the strongest quarterly ratio observed.
Valuation and Capital Efficiency
Entero Healthcare Solutions exhibits a return on capital employed (ROCE) of 8.6%, which is considered attractive within its sector. The company’s enterprise value to capital employed ratio is 2.2, indicating a valuation level that is discounted relative to its peers’ historical averages. This valuation context suggests that the market is pricing the stock conservatively despite the company’s growth in sales and profits.
Over the past year, while the stock price has declined by 32.58%, the company’s profits have increased by 142%. This disparity is reflected in a price/earnings to growth (PEG) ratio of 0.3, which is relatively low and points to a valuation that does not fully reflect earnings growth.
Debt Servicing and Institutional Ownership
Financial leverage appears manageable, with a debt to EBITDA ratio of 1.33 times. This level indicates a capacity to service debt obligations without excessive strain. Institutional investors hold 24.32% of the company’s shares, representing a significant stake by entities with extensive resources and analytical capabilities.
Entero Healthcare Solutions or something better? Our SwitchER feature analyzes this small-cap Retailing stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Contextualising the Stock’s Performance Within the Retailing Sector
Entero Healthcare Solutions operates within the retailing industry, a sector that has experienced varied performance across different companies and market cycles. The stock’s recent price trajectory contrasts with broader market indices and sector averages, which have shown resilience or growth over comparable periods. The company’s market capitalisation grade is noted as 3, reflecting its mid-cap status and relative size within the market.
The stock’s persistent trading below key moving averages and its underperformance relative to the Sensex and sector benchmarks underscore the challenges faced in regaining investor confidence. The absence of price appreciation over multi-year horizons further highlights the stock’s subdued market standing.
Summary of Key Financial and Market Indicators
To summarise, Entero Healthcare Solutions’ stock price has reached a historic low of Rs.952.5, with a one-day decline of 1.23% on 26 December 2025. The stock’s performance over one month, three months, one year, and year-to-date periods has lagged behind the Sensex by significant margins. Despite this, the company’s net sales and operating profits have shown strong growth rates, and it maintains a manageable debt profile. Valuation metrics suggest the stock is trading at a discount compared to peers, while institutional ownership remains substantial.
These factors collectively paint a complex picture of a company with solid underlying financial growth but facing persistent market valuation challenges.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
